|
 The approval came from the Drugs Controller General of India (DCGI),
according to the source.
AstraZeneca has resumed British clinical trials of the vaccine, one
of the most advanced in development for COVID-19, after they were
paused earlier this month following a serious side effect in a trial
participant.
Trials have also resumed in Brazil and South Africa, but remain on
hold in the United States.
Indian regulators had allowed Serum's trials of the AstraZeneca
vaccine to resume under certain conditions, including increased
safety monitoring and informing volunteers about new findings, a
DCGI source said.
[to top of second column] |
"We allowed them (to resume trials) after a detailed discussion with
authorities in the UK and the company itself," the source added.
Serum, the world's biggest vaccine manufacturer, did not respond to
Reuters requests for comment, while DCGI representatives did not
respond to emails seeking comment.
(Reporting by Euan Rocha in Mumbai, Neha Dasgupta in New Delhi and
Sachin Ravikumar in Bengaluru; Editing by Anil D'Silva and Shounak
Dasgupta)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
